Naltrexone Sustained Release Formulation via 3-Acyl Derivatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing sustained release naltrexone formulations face challenges such as complex manufacturing processes, inaccessible administration procedures, low drug loading, and fluctuating release profiles, which limit their therapeutic duration and effectiveness in treating opioid use disorder and alcoholism.
Innovation Solution
The development of an injectable sustained release pharmaceutical formulation comprising 3-acyl-naltrexone derivatives or their pharmaceutically acceptable salts, combined with a biocompatible solvent and optionally a biocompatible polymeric material, which provides a sustained release of naltrexone for at least one week to several months.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If existing sustained release naltrexone formulations are used, then therapeutic duration is extended, but manufacturing complexity increases and drug loading decreases
Solution Approach 1:
The patent modifies the chemical structure of naltrexone by creating ester derivatives at the 3-hydroxyl group with various acyl chains of different lengths and structures. This parameter change in molecular structure directly affects the release profile and therapeutic duration while using simple injectable formulations, avoiding complex manufacturing processes.
Solution Approach 2:
The formulation combines naltrexone ester derivatives with biocompatible solvents and optionally biocompatible polymeric materials to create a composite injectable system. This composite approach enables sustained release over extended periods while maintaining simple formulation and manufacturing processes.
2Duration of action of stationary object
If existing sustained release naltrexone formulations are used, then therapeutic duration is extended, but administration accessibility decreases
Solution Approach 1:
By changing the chemical parameters of naltrexone to ester derivatives, the formulation achieves sustained release that extends therapeutic duration while maintaining simple injectable administration, improving accessibility compared to complex delivery systems.
3Duration of action of stationary object
If existing sustained release naltrexone formulations are used, then release profile is extended, but release stability fluctuates
Solution Approach 1:
Systematic modification of the acyl chain parameters (length, branching, saturation) in naltrexone ester derivatives allows optimization of the release profile. Specific acyl chain configurations provide stable, predictable release patterns over extended durations.
Solution Approach 2:
The patent employs pharmacokinetic studies and in vitro dissolution testing to evaluate and optimize the release profile of different naltrexone ester derivatives, using this feedback information to select the optimal derivative that provides stable release characteristics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This formulation offers an accessible administration procedure, a sustained release profile, and a long therapeutic duration, maintaining effective plasma concentrations of naltrexone for extended periods, thus enhancing treatment efficacy for opioid use disorder and alcoholism.
Implementation Method 1
The present disclosure provides an injectable sustained release pharmaceutical formulation comprising 3-acyl-naltrexone derivative or a pharmaceutically acceptable salt thereof
Data Source
AI summary
Provided is an injectable sustained release pharmaceutical formulation, including 3-acyl-naltrexone or a pharmaceutically acceptable salt thereof, a biocompatible organic solvent, and optionally a biocompatible polymeric material. Also provided is a method for treating opioid use disorder or alcoholism, including administering the injectable sustained release pharmaceutical formulation to a subject in need thereof. The pharmaceutical formulation provides a sustained release profile after one single injection, and the plasma levels of naltrexone in minipigs could provide a sustained release for 2 months.